Are administered treatment with any other investigational agent or participation in another clinical study with anti-cancer therapeutic intent
Participation in another therapeutic clinical study or receiving any investigational agent within 28 days of enrollment or during this clinical study
Treatment with any other investigational agent or participation in another clinical study with therapeutic intent
Participation in any other clinical trial within 4 weeks prior to randomization.
Participation in any other clinical trial involving another investigational agent within 4 weeks prior to Day 1 of the study.
Participation in any clinical trial, within four weeks prior to registration on this trial, which involved an investigational drug or device
Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days or five half-lives of the drug prior to enrollment
Participation in any other clinical trial involving another investigational agent within 4 weeks prior to first dose of study agent
Participation in any other clinical trial involving another investigational agent within 4 weeks prior to first dosing of study drug
Participation in any other clinical trial involving another investigational agent within 4 weeks prior to first immunization
Treatment with any other investigational agent or participation in another clinical study with therapeutic intent within 30 days prior to randomization
Subjects may not be receiving any other investigational agents or have participated in any other clinical trial involving another investigational agent for treatment of advanced solid tumors or lymphoma within 3 weeks prior to cycle 1, day 1 of the study.
Treatment with any investigational agent on a different clinical trial within 30 days of enrollment
Treatment with any investigational agent on a different clinical trial within 30 days of lymphodepleting chemotherapy
Treatment with any investigational agent or on an interventional clinical trial within 30 days prior to treatment on protocol
Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days prior to enrollment
Treatment with any other investigational agent or participation in another clinical trial within 28 days prior to study entry;
Participation in a trial of an investigational agent within the prior 30 days
Treatment with any investigational agent or on an interventional clinical trial within 30 days prior to registration
Participation in an investigational therapeutic drug trial within 30 days of study entry
Participation in any other clinical trial involving another investigational agent for the treatment of AML within 2 weeks prior to day 1 of the study or at least 5 half-lives of the investigational agent, whichever is shorter
Participation in another clinical trial with any investigative drug within 30 days prior to study enrolment
Participation in another clinical trial with drug intervention within 21 days prior to start of cycle 1 and during the study
Treatment with any other investigational agent, or participation in another investigational drug trial within 28 days prior to randomization
Participation in another investigational trial within 90 days
Participation in another interventional clinical trial or treatment with any investigational drug within 4 weeks prior to study entry.
Concurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational drug within 4 weeks prior to study entry.
Participation in an investigational trial within 30 days of study entry
Concurrent participation in an investigational drug trial with therapeutic intent defined as prior study therapy within 28 days prior to start of this study
Treatment with any other investigational agent, or participation in another investigational drug trial within 28 days prior to randomization
Concurrent participation in a clinical trial which involves another investigational agent
Participation in another clinical trial/investigation within 28 days prior to study drug
Treatment with any other test drug or participation in another clinical trial within 28 days of enrollment.
Participation in a clinical trial with an investigational therapy within 30 days prior to randomization
Participation in another clinical trial with any investigational drug within 30 days prior to study entry.
Concurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational not marketed drug within 30 days prior to randomization.
Concurrent participation in an investigational drug trial with therapeutic intent
Prior treatment in any other clinical trial involving another investigational agent within 4 weeks prior to Day -31 of the study; resolution of respective adverse event to Grade 1 or lower should have occurred
Systemic treatment on any investigational clinical trial within 28 days prior to registration.
Participation in a clinical trial involving an investigational drug within 30 days of study start
Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days prior to enrollment
Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days prior to enrollment
Current enrollment in another clinical trial involving treatment and/or is receiving an investigational agent for any reason
Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days prior to enrollment
Participation in an investigational therapeutic drug trial within 30 days of study entry
Participation in another investigational drug clinical trial
Current enrollment in another clinical trial involving treatment and/or is receiving an investigational agent for any reason
Patients who have participated in any therapeutic clinical study/received any investigational agent within the last 30 days are excluded from participation in this trial.
Participation in another investigational drug clinical trial.
Participation in another clinical trial with drug intervention within 28 days prior to start of Cycle 1 and during study
E 09. Participation in another clinical trial and any concurrent treatment with any investigational drug within 30 days prior to randomization.
Concurrent participation or participation within the last 30 days prior to enrollment in any clinical trial with an investigational medicinal drug/chemotherapeutic or biologic or medical product.
Participation in another clinical trial or treatment with any investigational drug (excluding anticancer treatments) within 30 days of study start
Participation in any other clinical trial involving another investigational agent within 4 weeks prior to day 1 of the study.
Treatment with any other investigational agent, or participation in another investigational drug trial within 28 days prior to randomization
Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 4 weeks prior to the first dose of study treatment
Use of an investigational agent or participation in another clinical trial within 4 weeks prior to randomization
Participation in a trial of an investigational agent within the prior 30 days
Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days prior to enrollment; the following exceptions are allowed:\r\n* Unapproved/ experimental TKIs discontinued 14 days prior to cycle 1, day 1
Participation in another clinical trial and any concurrent treatment with any investigational drug within 30 days prior to randomization.
Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days prior to Day 1 of Cycle
Participation in another clinical trial and any concurrent treatment with any investigational drug within 30 days prior to study entry
Treatment with any other investigational agent or participation in another clinical trial within 28 days prior to the start of Cycle 1
Participation in another clinical trial in which they received active therapy within 4 weeks prior to the first dose of study drug.
Participation in another clinical trial or use of any investigational drug within 30 days prior to study entry
Concurrent treatment with an investigational agent or participation in another treatment clinical trial;
Treatment with any other investigational agent or participation in another clinical study with therapeutic intent within 28 days prior to enrollment
Participation in any other clinical trial involving another investigational agent within 4 weeks prior to first dosing of study drug
Investigational treatment or clinical trial within 4 weeks.
Current participation in a trial with another investigational agent, unless co-enrollment is approved by the principal investigators (PIs) of both studies
Participation in another clinical trial or use of another investigational agent within 30 days of study entry
Concurrent participation in a clinical trial which involves another investigational agent
Participation in another clinical trial involving an investigational product within 30 days prior to screening; or
The use of any investigational agent within 30 days preceding the first dose of the study vaccine or subsequent participation in another clinical trial at any time during the study period, in which the subject will be exposed to an investigational product
Receiving another investigational agent on a clinical trial that prohibits participation in other studies of investigational agents
Participation in another clinical trial involving an investigational agent within 4 weeks of enrollment
Participant in a clinical trial involving an investigational drug within the past 30 days
Having received an investigational drug in an investigational drug trial within the last 30 days before randomization for this clinical trial. Participation in a clinical trial without receiving other investigational drugs (e.g. follow-up phase of a trial, observational study) is permitted. Part B, Exclusion criteria: All exclusion criteria as for Part A, except for inclusion criteria 1 and 12 which are replaced by:
Known intolerance to pritelivir or any of the excipients and 12. Having received an investigational drug in an investigational drug trial within the last 30 days before Day 1 for this clinical trial (except for subjects entering Part B who have previously received foscarnet treatment in Part A of this trial). Participation in a clinical trial without receiving other investigational drugs (e.g. follow-up phase of a trial, observational study) is permitted.
Patient included in another clinical trial involving an IMP within 30 days before the first investigational contrast agent injection.
Treatment with any other investigational agent or participation in another clinical study with therapeutic intent within 28 days prior to enrolment
